The Hippo Pathway as a Driver of Select Human Cancers
- PMID: 32446746
- DOI: 10.1016/j.trecan.2020.04.004
The Hippo Pathway as a Driver of Select Human Cancers
Abstract
The Hippo pathway regulates myriad biological processes in diverse species and is a key cancer signaling network in humans. Although Hippo has been linked to multiple aspects of cancer, its role in this disease is incompletely understood. Large-scale pan-cancer analyses of core Hippo pathway genes reveal that the pathway is mutated at a high frequency only in select human cancers, including malignant mesothelioma and meningioma. Hippo pathway deregulation is also enriched in squamous epithelial cancers. We discuss cancer-related functions of the Hippo pathway and potential explanations for the cancer-restricted mutation profile of core Hippo pathway genes. Greater understanding of Hippo pathway deregulation in cancers will be essential to guide the imminent use of Hippo-targeted therapies.
Keywords: Hippo pathway; meningioma; mesothelioma; pan-cancer analysis.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.Cancer Lett. 2017 Jan 28;385:215-224. doi: 10.1016/j.canlet.2016.10.020. Epub 2016 Oct 20. Cancer Lett. 2017. PMID: 27773750
-
Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.Clin Cancer Res. 2015 Nov 15;21(22):5002-7. doi: 10.1158/1078-0432.CCR-15-0411. Epub 2015 Sep 17. Clin Cancer Res. 2015. PMID: 26384319 Free PMC article.
-
Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.Cancer Lett. 2021 Jun 1;507:112-123. doi: 10.1016/j.canlet.2021.03.006. Epub 2021 Mar 15. Cancer Lett. 2021. PMID: 33737002 Free PMC article. Review.
-
Ubiquitination‑deubiquitination in the Hippo signaling pathway (Review).Oncol Rep. 2019 Mar;41(3):1455-1475. doi: 10.3892/or.2019.6956. Epub 2019 Jan 8. Oncol Rep. 2019. PMID: 30628704 Review.
-
Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.J Biol Chem. 2018 Jan 26;293(4):1178-1191. doi: 10.1074/jbc.RA117.000392. Epub 2017 Nov 28. J Biol Chem. 2018. PMID: 29183995 Free PMC article.
Cited by
-
Comparative Assessment and High-Throughput Drug-Combination Profiling of TEAD-Palmitoylation Inhibitors in Hippo Pathway Deficient Mesothelioma.Pharmaceuticals (Basel). 2023 Nov 21;16(12):1635. doi: 10.3390/ph16121635. Pharmaceuticals (Basel). 2023. PMID: 38139762 Free PMC article.
-
Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy.Front Pharmacol. 2021 Dec 17;12:720474. doi: 10.3389/fphar.2021.720474. eCollection 2021. Front Pharmacol. 2021. PMID: 34975466 Free PMC article. Review.
-
Narciclasine is a novel YAP inhibitor that disturbs interaction between YAP and TEAD4.BBA Adv. 2021 Mar 27;1:100008. doi: 10.1016/j.bbadva.2021.100008. eCollection 2021. BBA Adv. 2021. PMID: 37082014 Free PMC article.
-
Mechanisms of cellular crosstalk in the gastric tumor microenvironment are mediated by YAP1 and STAT3.Life Sci Alliance. 2023 Nov 13;7(2):e202302411. doi: 10.26508/lsa.202302411. Print 2024 Feb. Life Sci Alliance. 2023. PMID: 37957015 Free PMC article.
-
FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.Biomolecules. 2024 Oct 14;14(10):1297. doi: 10.3390/biom14101297. Biomolecules. 2024. PMID: 39456230 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
